About Pangen Biotech
Pangen Biotech is a company based in Gyeongju (South Korea) founded in 2010. The company has 75 employees as of December 31, 2024. Pangen Biotech operates in a competitive market with competitors including TScan Therapeutics, GigaGen, Shattuck Labs, Boundless Bio and Bolt Biotherapeutics, among others.
- Headquarter Gyeongju, South Korea
- Employees 75 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pangen Biotech, Inc.
-
Annual Revenue
$9.95 M (USD)100.58as on Dec 31, 2024
-
Net Profit
$639.82 K (USD)0as on Dec 31, 2024
-
EBITDA
$1.54 M (USD)0as on Dec 31, 2024
-
Latest Funding Round
$10.23 M (USD), Post-IPO
Nov 07, 2024
-
Investors
Huons
& 1 more
-
Employee Count
75
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Pangen Biotech
Pangen Biotech is a publicly listed company on the KRX with ticker symbol 222110 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Pangen Biotech
Investors in Pangen Biotech
Pangen Biotech has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Huons and CrystalGenomics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Limited information is available on core activities of Huons.
|
Locked | Locked | Locked | |
|
Clinical stage pharmacy company focused on the novel drugs in areas of inflammation, oncology, and infectious disease
|
Locked | Locked | Locked |
Investor details for Pangen Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pangen Biotech
Investment portfolio details for Pangen Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pangen Biotech
Detailed financials for Pangen Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pangen Biotech Comparisons
Peer comparison for Pangen Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pangen Biotech
Pangen Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, GigaGen, Shattuck Labs, Boundless Bio and Bolt Biotherapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms.
|
|
| Locked | Locked | Locked |
An immunotherapy platform for oncology and other diseases is developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer are developed by targeting ecDNA.
|
|
| Locked | Locked | Locked |
T-cell therapies for cancer treatment are developed by Bolt Biotherapeutics.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
Detailed competitors of Pangen Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pangen Biotech
Complete news archive for Pangen Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pangen Biotech
Pangen Biotech was founded in 2010 and raised its 1st funding round 12 years after it was founded.
Pangen Biotech is headquartered in Gyeongju, South Korea. It is registered at Gyeongju, North Gyeongsang Province, South Korea.
Jae Hong Jang is the current CEO of Pangen Biotech.
As of Dec 31, 2024, the latest employee count at Pangen Biotech is 75.
Annual revenue of Pangen Biotech is $9.95M as on Dec 31, 2024.
Pangen Biotech was established in 2010 as a player in the biotechnology sector. Biosimilars and biologics, including EPO, Factor VIII, and G-CSF, are developed by the company. Emphasis is placed on the development and commercialization of these products. Operations involve research and market introduction within the biologics field, with key leadership provided by executives such as Jae Hong Jang and Youngboo Kim.
Pangen Biotech's top competitors include Lyell Immunopharma, GigaGen and Shattuck Labs.
Yes, Pangen Biotech is publicly traded on KRX under the ticker symbol 222110.
Pangen Biotech has 2 investors. Key investors include Huons, and CrystalGenomics.
The ticker symbol of Pangen Biotech is 222110 on KRX.